SEHK:8037

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

China Biotech Services Holdings

Executive Summary

China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has China Biotech Services Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8037 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

5.4%

8037

4.3%

HK Healthcare

1.4%

HK Market


1 Year Return

-10.6%

8037

-30.6%

HK Healthcare

-9.9%

HK Market

Return vs Industry: 8037 exceeded the Hong Kong Healthcare industry which returned -30.6% over the past year.

Return vs Market: 8037 matched the Hong Kong Market which returned -9.9% over the past year.


Shareholder returns

8037IndustryMarket
7 Day5.4%4.3%1.4%
30 Day4.4%-3.5%-3.7%
90 Day-1.7%-13.4%-7.8%
1 Year-10.6%-10.6%-29.0%-30.6%-6.9%-9.9%
3 Year122.6%122.6%-46.4%-49.5%-4.8%-14.4%
5 Year28.7%1.7%-55.2%-59.0%-15.2%-28.3%

Price Volatility Vs. Market

How volatile is China Biotech Services Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is China Biotech Services Holdings undervalued compared to its fair value and its price relative to the market?

3.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 8037's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 8037's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 8037 is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: 8037 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8037's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8037 is overvalued based on its PB Ratio (4x) compared to the HK Healthcare industry average (1.2x).


Next Steps

Future Growth

How is China Biotech Services Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Biotech Services Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has China Biotech Services Holdings performed over the past 5 years?

-11.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8037 is currently unprofitable.

Growing Profit Margin: 8037 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8037 is unprofitable, and losses have increased over the past 5 years at a rate of -11.7% per year.

Accelerating Growth: Unable to compare 8037's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8037 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7%).


Return on Equity

High ROE: 8037 has a negative Return on Equity (-37.41%), as it is currently unprofitable.


Next Steps

Financial Health

How is China Biotech Services Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 8037's short term assets (HK$86.4M) exceed its short term liabilities (HK$53.8M).

Long Term Liabilities: 8037's short term assets (HK$86.4M) exceed its long term liabilities (HK$49.5M).


Debt to Equity History and Analysis

Debt Level: 8037's debt to equity ratio (9.2%) is considered satisfactory.

Reducing Debt: 8037's debt to equity ratio has reduced from 15% to 9.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 8037 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 8037 has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 12.2% each year.


Next Steps

Dividend

What is China Biotech Services Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8037's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 8037's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8037's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8037's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8037's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

China Biotech Services Holdings has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Xiaolin Liu
Executive Co-Chairman1.08yrsHK$6.15m54.72% HK$608.9m
Yi Yao
Executive Co-Chairman of the Board1.08yrsHK$2.69mno data
Song Huang
CTO & Executive Director2.75yrsHK$1.64mno data
Pak Hou Leung
Compliance Officer & Executive Director7.08yrsHK$1.33mno data
Zheng Wang
Executive Director2.83yrsHK$2.14mno data
Xun He
Executive Director1.83yrsHK$480.00kno data
Miu Shun Wong
Company Secretary2.67yrsno datano data
Sze Ma
Head of Operation - DVF Groupno datano datano data
Sau Yan Wah
Head of Quality - DVF Holdco (Cayman) Limitedno datano datano data

2.7yrs

Average Tenure

51yo

Average Age

Experienced Management: 8037's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Xiaolin Liu
Executive Co-Chairman1.08yrsHK$6.15m54.72% HK$608.9m
Yi Yao
Executive Co-Chairman of the Board1.08yrsHK$2.69mno data
Song Huang
CTO & Executive Director2.75yrsHK$1.64mno data
Pak Hou Leung
Compliance Officer & Executive Director7.08yrsHK$1.33mno data
Zheng Wang
Executive Director2.83yrsHK$2.14mno data
Xun He
Executive Director1.83yrsHK$480.00kno data
Guoxiang Yan
Independent Non-Executive Director2.83yrsHK$240.00kno data
Qian Hongji
Independent Non-Executive Director2.25yrsHK$240.00kno data
Chun Kit Ho
Independent Non-Executive Director1.5yrsHK$240.00kno data

2.3yrs

Average Tenure

49yo

Average Age

Experienced Board: 8037's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China Biotech Services Holdings Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: China Biotech Services Holdings Limited
  • Ticker: 8037
  • Exchange: SEHK
  • Founded: 1996
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: HK$1.113b
  • Shares outstanding: 967.61m
  • Website: https://www.cbshhk.com

Number of Employees


Location

  • China Biotech Services Holdings Limited
  • Sino Plaza
  • Room 1904-5A
  • Causeway Bay
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
8037SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDJan 2005

Biography

China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services. It operates through Immunotherapy, Pharmaceutical Products, Medical and Health Related Services, Securities, Insurance brokerage, and Others segments. The company also engages in the research, development, manufacture, sale, and distribution of health related and pharmaceutical products; trading of securities; money lending business; provision of tumor immune cell therapy, immune cell storage, and health management services; and provision of coordination of healthcare providers services. In addition, it markets and sells health supplements, Chinese medicines, slimming pills, and beauty products; trades in pharmaceutical intermediates; and offers insurance brokerage services. Further, the company provides molecular diagnostic test and genetic investigation, and property investment services. It has operations in the People’s Republic of China and Hong Kong. China Biotech Services Holdings Limited has a strategic cooperation agreement with the Nanjing Medical University. The company was formerly known as Rui Kang Pharmaceutical Group Investments Limited and changed its name to China Biotech Services Holdings Limited in November 2017. China Biotech Services Holdings Limited was founded in 1996 and is headquartered in Causeway Bay, Hong Kong. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/01 13:06
End of Day Share Price2020/06/01 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.